 Unum Therapeutics Inc. UMRX, a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced it has entered into a common stock purchase agreement for up to 25 million with Lincoln Park Capital Fund, LLC LPC, a Chicago-based institutional investor. Under the terms of the purchase agreement, Unum Therapeutics will have the sole discretion, but not the obligation, to direct LPC to purchase up to 25 million in shares of its common stock over the 36-month term of the agreement. 